Lohse M J, Klotz K N, Schwabe U, Cristalli G, Vittori S, Grifantini M
Pharmakologisches Institut, Heidelberg, Federal Republic of Germany.
Naunyn Schmiedebergs Arch Pharmacol. 1988 Jun;337(6):687-9. doi: 10.1007/BF00175797.
2-Chloro-N6-cyclopentyladenosine (CCPA) was synthesized as a potential high affinity ligand for A1 adenosine receptors. Binding of [3H]PIA to A1 receptors of rat brain membranes was inhibited by CCPA with a Ki-value of 0.4 nM, compared to a Ki-value of 0.8 nM for the parent compound N6-cyclopentyladenosine (CPA). Binding of [3H]NECA to A2 receptors of rat striatal membranes was inhibited with a Ki-value of 3900 nM, demonstrating an almost 10,000-fold A1-selectivity of CCPA. CCPA inhibited the activity of rat fat cell membrane adenylate cyclase, a model for the A1 receptor, with an IC50-value of 33 nM, and it stimulated the adenylate cyclase activity of human platelet membranes with an EC50-value of 3500 nM. The more than 100-fold A1-selectivity compares favourably with a 38-fold selectivity of CPA. Thus, CCPA is an agonist at A1 adenosine receptors with a 4-fold higher selectivity and 2-fold higher affinity than CPA, and a considerably higher selectivity than the standard A1 receptor agonist R-N6-phenylisopropyladenosine (R-PIA). CCPA represents the agonist with the highest selectivity for A1 receptors reported so far.
2-氯-N6-环戊基腺苷(CCPA)被合成作为一种潜在的A1腺苷受体高亲和力配体。CCPA抑制[3H]PIA与大鼠脑膜A1受体的结合,其Ki值为0.4 nM,而母体化合物N6-环戊基腺苷(CPA)的Ki值为0.8 nM。[3H]NECA与大鼠纹状体膜A2受体的结合被抑制,Ki值为3900 nM,表明CCPA对A1受体具有近10000倍的选择性。CCPA抑制大鼠脂肪细胞膜腺苷酸环化酶的活性(A1受体的一种模型),IC50值为33 nM,并且它以3500 nM的EC50值刺激人血小板膜的腺苷酸环化酶活性。超过100倍的A1选择性优于CPA的38倍选择性。因此,CCPA是A1腺苷受体的激动剂,其选择性比CPA高4倍,亲和力高2倍,并且选择性比标准A1受体激动剂R-N6-苯基异丙基腺苷(R-PIA)高得多。CCPA是迄今为止报道的对A1受体选择性最高的激动剂。